New research presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, Sept. 28–Oct. 2, and published in The Lancet shows that, for people with type 2 diabetes at increased cardiovascular risk, a daily orforglipron pill had cardiovascular safety comparable to daily insulin glargine injections while providing greater improvements in weight and blood sugar control. However, gastrointestinal (GI) adverse events were more common with orforglipron, leading to more treatment discontinuations. The study was sponsored by Eli Lilly, the manufacturer of orforglipron.